Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease

PLoS One. 2016 Nov 16;11(11):e0166484. doi: 10.1371/journal.pone.0166484. eCollection 2016.

Abstract

Background: The X-chromosomally linked life-limiting Fabry disease (FD) is associated with deposits of the sphingolipid globotriaosylceramide 3 (Gb3) in various tissues. Skin is easily accessible and may be used as an additional diagnostic and follow-up medium. Our aims were to visualize skin Gb3 deposits in FD patients applying immunofluorescence and to determine if cutaneous Gb3 load correlates with disease severity.

Methods: At our Fabry Center for Interdisciplinary Therapy we enrolled 84 patients with FD and 27 healthy controls. All subjects underwent 5-mm skin punch biopsy at the lateral lower leg and the back. Skin samples were processed for immunohistochemistry using antibodies against CD77 (i.e. Gb3). Cutaneous Gb3 deposition was quantified in a blinded manner and correlated to clinical data.

Results: We found that Gb3 load was higher in distal skin of male FD patients compared to healthy controls (p<0.05). Men (p<0.01) and women (p<0.05) with a classic FD phenotype had higher distal skin Gb3 load than healthy controls. Men with advanced disease as reflected by impaired renal function, and men and women with small fiber neuropathy had more Gb3 deposits in distal skin samples than males with normal renal function (p<0.05) and without small fiber neuropathy. Gb3 deposits were not different between patients with and without enzyme replacement therapy.

Conclusions: Immunofluorescence on minimally invasive skin punch biopsies may be useful as a tool for assessment and follow-up in FD patients.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Biopsy
  • Case-Control Studies
  • Demography
  • Fabry Disease / metabolism*
  • Fabry Disease / pathology*
  • Female
  • Humans
  • Male
  • Middle Aged
  • ROC Curve
  • Severity of Illness Index
  • Skin / innervation
  • Skin / metabolism*
  • Skin / pathology*
  • Trihexosylceramides / metabolism*
  • Young Adult

Substances

  • Trihexosylceramides
  • globotriaosylceramide

Grants and funding

The study was supported by intramural research funds of the University of Würzburg and by an unrestricted grant to the University of Würzburg by Genzyme Corp. The sponsor had no knowledge of the study design and the results and also had no influence on the conductance of the project. Claudia Sommer and Nurcan Üçeyler received funding by the European Union's Seventh Framework Programme (“ncRNAPain”, grant agreement number 602133). This work was part of the doctoral theses of Nils Schröter, who received a six-months scholarship form the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG; Sonderforschungsbereich 581). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.